Abrocitinib Synthesis Patent Status
The synthesis of abrocitinib is covered by patents, which are crucial for protecting the intellectual property of the drug's manufacturing process. Information regarding specific patents and their expiration dates can be found through specialized resources [1].
When is the Abrocitinib Patent Expected to Expire?
Patent expiration dates for pharmaceuticals like abrocitinib determine when generic versions may enter the market. Detailed patent information, including expiration timelines, is available from sources tracking drug patents [1].
Who Holds the Patents for Abrocitinib?
Patents for abrocitinib are held by the originating pharmaceutical company, Pfizer. These patents cover various aspects of the drug, including its synthesis, formulation, and uses [2].
What Aspects of Abrocitinib Synthesis Are Patented?
Patents typically protect novel and inventive steps in the chemical synthesis of a drug molecule. For abrocitinib, this would likely include specific reactions, intermediates, reagents, and purification methods that are considered unique and efficient for its production [1].
Can Generic Abrocitinib Be Made Before Patent Expiry?
Manufacturing generic versions of abrocitinib before the relevant synthesis patents expire is generally not permitted due to patent infringement. Generic manufacturers must wait for patent protections to lapse or secure licensing agreements to produce the drug [1].
How Does DrugPatentWatch.com Track Abrocitinib Patents?
DrugPatentWatch.com provides a database of drug patents, including those related to abrocitinib. The platform tracks patent filings, grants, and expiration dates, offering insights into the patent landscape and potential market entry for generics [1].
*
**Sources
1. https://drugpatentwatch.com/
2. Pfizer Inc.